News

Phase 3 MIRANDA found tozorakimab reduced COPD exacerbations in former smokers despite inhaled maintenance therapy.

Etavopivat reduced VOC events by 27% and improved hemoglobin response in the phase 3 HIBISCUS trial in sickle cell disease.

Aliza Narva, JD, discusses how clinical ethics consultation works in practice, from bedside dilemmas to mediation-based approaches and clinician support.

Beck discusses the recently presented results of INHALE-1, in which technosphere insulin failed to prove noninferiority to RAA but had no pulmonary effects.

Listen to our conversation with Trachtman about sparsentan's recent FDA approval for FSGS.

In a Q&A from AAD 2026, Elmariah highlights a variety of significant results highlighted in a poser session from the RELIEVE-PN study regarding dupilumab for prurigo nodularis.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.

Tozorakimab significantly reduced moderate-to-severe exacerbations in COPD regardless of blood eosinophil count.

At AAD, April W. Armstrong, MD, MPH, discussed recent innovations in the atopic dermatitis treatment space, highlighting long-term safety data and more.

Beck discusses a recent analysis of the phase 4 trial comparing TI and degludec against standard treatment, highlighting the need for individualized titration.

Hanna describes the "freedom" patients with sickle cell disease reported after being treated with reni-cel, a one-time edited gene therapy.

View slated expert interviews and 7 clinical trials to watch at AACE Annual Meeting 2026.

In this Q&A interview, Ferrucci highlights key real-world findings from the GLOBOSTAD on the safety and efficacy of dupilumab (Dupixent) in atopic dermatitis.

Data from a study deploying mobile health units across Detroit, Michigan, found CKD stage ≥3 rates double the national average and increased rates in at-risk subgroups.

Blauvelt discusses studies revealing that disease severity, injection frequency, pain, and geography all shape treatment preferences.

Armstrong highlights several major takeaways from her portion of the AAD 2026 session titled 'IL-23 Innovation: New Data Addressing Plaque Psoriasis.'

This episode explores the launch and accessibility of FDA-approved oral GLP-1 orforglipron, including availability through Amazon Pharmacy's same-day delivery service.

Patel provides an inside perspective on one of the most diagnostically challenging cardiovascular conditions.

Hosts are joined by Meena Bansal, MD, to discuss long-standing research gaps and what clinicians need to understand about sex-specific drivers of liver disease today.

Murrough discusses ADAA 2026 findings evaluating azetukalner in MDD with anhedonia; exploratory outcomes suggest potential benefit despite nonsignificant primary endpoints.

Hanna, MD, shares results from reni-cel, a one-time gene editing therapy for patients with sickle cell disease.

Nambudiri discusses the AAD Clinical Image Collection, launched in January 2025 to address the lack of diverse representation in dermatology education.

Experts discuss diagnostic challenges, variable presentations, and strategies to improve outcomes in Wilson disease.

Extension data through week 54 reveal deepening responses with povorcitinib in moderate-to-severe HS.

This Q&A interview highlights several takeaways from the data on upadacitinib in patients with non-segmental vitiligo (NSV).

Evidence from 3 recent studies explores microbiome modulation, early allergen exposure, and immune tolerance as pathways for food allergy prevention.

Clinicians discuss diagnostic gaps, treatment strategies, and multidisciplinary care in Wilson disease.

HS is associated with up to a nearly 2-fold increased risk of heart failure, coronary artery disease, myocardial infarction, venous thromboembolism, and all-cause mortality.